Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
8059 ARTÍCULOS , VIENDO DEL 3331 AL 3345
Matsunaga S, Fujishiro H, Takechi H.
J Alzheimers Dis. 2019;69(4):1031-1039. doi: 10.3233/JAD-190256.
An augmented reality approach for ADL support in Alzheimer's disease: a crossover trial
Rohrbach N, Gulde P, Armstrong AR, Hartig L, Abdelrazeq A, Schröder S, Neuse J, Grimmer T, Diehl-Schmid J, Hermsdörfer J.
J Neuroeng Rehabil. 2019 Jun 3;16(1):66. doi: 10.1186/s12984-019-0530-z.
González JF, Alcántara AR, Doadrio AL, Sánchez-Montero JM.
Expert Opin Drug Discov. 2019 Sep;14(9):879-891. doi: 10.1080/17460441.2019.1623201. Epub 2019 Jun 5.
Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease
Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctôt KL.
Am J Geriatr Psychiatry. 2019 Nov;27(11):1161-1173. doi: 10.1016/j.jagp.2019.05.002. Epub 2019 May 8.
Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment
Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, Abbaszadeh H, Aghebati-Maleki L, Pourlak T, Mehdizadeh A, Yousefi M.
Life Sci. 2019 Aug 15;231:116564. doi: 10.1016/j.lfs.2019.116564. Epub 2019 Jun 13.
Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?
Willbold D, Kutzsche J.
Molecules. 2019 Jun 15;24(12):2237. doi: 10.3390/molecules24122237.
Hossain MF, Uddin MS, Uddin GMS, Sumsuzzman DM, Islam MS, Barreto GE, Mathew B, Ashraf GM.
Mol Neurobiol. 2019 Dec;56(12):8255-8276. doi: 10.1007/s12035-019-01660-3. Epub 2019 Jun 17.
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML.
Curr Top Med Chem. 2019;19(19):1694-1711. doi: 10.2174/1568026619666190619115735.
The overlap between epilepsy and Alzheimer's disease and the consequences for treatment
Powell G, Ziso B, Larner AJ.
Expert Rev Neurother. 2019 Jul;19(7):653-661. doi: 10.1080/14737175.2019.1629289. Epub 2019 Jun 26.
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma K.
Mol Med Rep. 2019 Aug;20(2):1479-1487. doi: 10.3892/mmr.2019.10374. Epub 2019 Jun 11.
Autophagy Dysfunction in Alzheimer's Disease: Mechanistic Insights and New Therapeutic Opportunities
Di Meco A, Curtis ME, Lauretti E, Praticò D.
Biol Psychiatry. 2020 May 1;87(9):797-807. doi: 10.1016/j.biopsych.2019.05.008. Epub 2019 May 20.
Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H.
Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17.
Current and emerging avenues for Alzheimer's disease drug targets
Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B.
J Intern Med. 2019 Oct;286(4):398-437. doi: 10.1111/joim.12959. Epub 2019 Aug 29.
Serious Illness and End-of-Life Treatments for Nurses Compared with the General Population
Bynum J, Passow H, Austin A, Carmichael D, Grodstein F.
J Am Geriatr Soc. 2019 Aug;67(8):1582-1589. doi: 10.1111/jgs.16044. Epub 2019 Jul 9.
Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease
Vijayan DK, Zhang KYJ.
Pharmacol Res. 2019 Sep;147:104342. doi: 10.1016/j.phrs.2019.104342. Epub 2019 Jul 6.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.